Chapter 11 Pt 3– Cloning: Plants, Animals, and Stem-Cell Applications

Concept of Cloning – Core Ideas

• Cloning = creation of a new individual via asexual reproduction (no fusion of gametes).
• Relies on foundational principle (introduced earlier in Ch. 11): every differentiated cell still retains a full copy of the organism’s genome; only gene expression differs.
• Thus, if you reset gene-expression patterns, a mature cell can behave like a fertilized egg and direct development of a whole organism.
• Mitosis drives all divisions in the clone → each daughter cell receives an identical genome → resulting organism is genetically identical (a “clone”) of the donor.
• Two broad operational categories discussed:
  • Reproductive cloning – goal is a full organism.
  • Therapeutic cloning – goal is cells/tissues, not an entire individual.

Plant Cloning – Historical & Practical Context

• Humans have practiced plant cloning for millennia (implicit link: agriculture & horticulture).
• Everyday example: taking a cutting (“clipping”) from a friend’s plant, rooting it in soil/water → new plant genetically identical to the parent.
• Laboratory demonstration (carrot):
  • Start with root cells from a carrot (includes fine lateral roots often seen when you pull a carrot from soil).
  • Place cells in nutrient culture medium (“just right” balance of hormones & minerals).
  • Cells divide → form undifferentiated mass → regenerate shoots/roots → plantlet.
  • Once transferred to soil, develops into a mature adult carrot plant.
  • Genetic tests show $100\%$ identity between donor plant and clone.
• Significance: reveals totipotency of many plant cells and underpins commercial micro-propagation.

Animal Cloning – Nuclear Transplantation Method

• Technical name: somatic cell nuclear transfer (SCNT).
• Baseline workflow (same for frogs in $1950\text{s}$, first mammal $1997$, etc.):
  1. Obtain an unfertilized egg cell from donor-A.
  2. Enucleate it (remove haploid nucleus).
  3. Collect a differentiated somatic cell (e.g., skin fibroblast) from donor-B.
  4. Transfer nucleus of donor-B into enucleated egg (now contains a diploid genome).
  5. Electric/chemical stimulus mimics fertilization → egg “reprograms” nucleus → starts cleavage divisions.
  6. Culture embryo in vitro to blastocyst (~$100$ cells).
  7. Two possible routes:
     • Reproductive: implant blastocyst into surrogate uterus (donor-C) → full-term gestation.
     • Therapeutic: disaggregate blastocyst for stem-cell harvest (see later section).

Case Study – Dolly the Sheep

• Birth year: $1997$ – first cloned large mammal, headline news.
• Three contributing sheep:
  • Egg donor (enucleated oocyte).
  • Somatic-cell donor (udder/skin cell) – genetic twin of Dolly.
  • Surrogate mother (carried pregnancy).
• Biological twist: nucleus came from a $\sim6\text{-year-old}$ ewe → Dolly’s telomeres & epigenetic marks already “aged”; she experienced premature health issues.
• Demonstrated feasibility but highlighted limitations (incomplete reprogramming, epigenetic memory, telomere shortening).

Reproductive Cloning – Motivations & Examples

• Post-Dolly, technique extended to many mammals: cattle, goats, pigs, horses, cats, dogs, etc.
• Proposed/actual uses:
  • Agriculture: replicate elite livestock with superior musculature, milk yield, disease resistance → improve productivity & uniformity.
  • Biopharming / therapeutic agents: clone transgenic animals engineered to secrete human proteins (e.g., insulin in milk) or grow human-compatible organs (e.g., gene-edited pigs harvesting pancreases).
  • Conservation: restocking endangered species populations.
  – Critiqued as shortsighted: ↓ genetic diversity (all clones identical), ignores root causes (habitat loss, poaching), may reduce conservation urgency.
• Ethical/social concerns (especially human cloning):
  • Identity & individuality issues.
  • High failure/abnormality rates → welfare problems.
  • Potential commodification of human life.
  • Legal, religious, and societal objections.

Therapeutic Cloning – Stem-Cell–Focused Approach

• Objective: harvest embryonic stem cells (ESCs) from blastocyst without creating a born individual.
• ESC properties:
  • Pluripotent – can differentiate into virtually any cell type: neurons, cardiac muscle, pancreatic β-cells, hematopoietic lineages, etc.
  • Indefinite self-renewal in culture.
• Potential medical applications:
  • Regenerate damaged spinal-cord neurons (overcome loss of natural nerve regeneration).
  • Repair infarcted heart tissue, replace dead cardiomyocytes.
  • Produce insulin-secreting cells for diabetes.
  • Create patient-specific organs/tissues → reduce transplant rejection (if nucleus derived from patient).
• Core ethical debate: obtaining ESCs requires destruction of human embryos → ongoing legislative & moral controversy in many countries (U.S. citizens encouraged to stay informed and vote accordingly).

Adult Stem Cells – An Alternative Source

• Reside in small numbers within mature tissues (e.g., bone marrow, skin, intestine).
• Characteristics:
  • Multipotent, not pluripotent – typically restricted to a few related lineages (bone-marrow cells → various blood cells).
  • Less ethically contentious (harvested from patient’s own body).
  • Autologous use minimizes immune rejection.
• Current successes: bone-marrow transplants (hematopoietic stem cells), experimental work on induced expansion/differentiation into other lineages.
• Limitation: narrower developmental potential vs. ESCs, lower proliferation capacity.

Comparative Summary – ESC vs. Adult Stem Cells

• Source: embryo (ESC) vs. mature tissue (adult).
• Potency: ESC = pluripotent; adult = multipotent.
• Expansion: ESC divide indefinitely; adult stem cells have finite proliferative capacity.
• Ethical load: ESC high; adult low.
• Immunogenicity: ESC allogeneic unless created via nuclear transfer; adult typically autologous.

Overarching Significance & Continued Challenges

• Cloning validates the concept of genomic equivalence and highlights the role of epigenetic reprogramming.
• Technical hurdles: low success rates, developmental abnormalities, epigenetic memory, telomere attrition.
• Societal/ethical landscape continues to evolve: balancing medical promise against moral, ecological, and welfare concerns.

Key Numbers & Facts (encapsulated)

• Earliest frog SCNT: $1950\text{s}$.
• Dolly’s announcement: $1997$.
• Blastocyst cut-off size: $\approx100$ cells.
• Somatic-cell donor age in Dolly experiment: $6\text{ years}$.

Quick-Reference Takeaways

• Every differentiated cell contains the entire genome → basis for cloning.
• Plant cells often naturally totipotent → easy vegetative propagation.
• Animal cloning requires SCNT; success drops as organismal complexity rises.
• Reproductive cloning suited for agriculture & specialized bioproduction, but problematic for conservation or human application.
• Therapeutic cloning (ESC) offers broad regenerative potential yet faces ethical scrutiny; adult stem cells safer ethically but biologically restricted.